FDA approves Striverdi Respimat for COPD, includes asthma warning

  • July 31, 2014

The FDA has announced approval of olodaterol inhalation spray to treat patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, who experience airflow obstruction.

Olodaterol (Striverdi Respimat, Boehringer Ingelheim Pharmaceuticals) is a long-acting beta-adrenergic agonist (LABA) that allows muscles around the lungs’ airways to stay relaxed to prevent symptoms and can be used daily for an extended period, according to an FDA press release. LABAs increase the risk for asthma-related deaths, according to Striverdi Respimat’s boxed warning.

Full Story »

More »
More »
  • Blog
  • Editor Pick 2
  • Eye on Intervention
  • O. Steven Gigliotti, MD, FSCAI,, shares his thoughts after attending the Alliance of Specialty Medicine Legislative Fly-In in Washington, D.C.
More »
  • Commentary
  • Editor Pick 4
  • The future of phospholipase A2
  • Brian Houston, MD, and Seth S. Martin, MD, discuss the potential of phospholipase A2 as a therapeutic target for CHD
More »
More »
More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!